Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption. However, the mechanisms ...

Scientists at The University of Texas at Austin, in collaboration with researchers from the University of North Carolina at Chapel Hill and the National Institutes of Health, have discovered a ...

An HIV vaccine candidate developed at the Duke Human Vaccine Institute (DHVI) triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a ...

“Our results show how different factors boost the formation of antibodies that broadly combat different viral strains. This will pave the way for us to systematically push ahead with the development ...

Researchers have developed a GPS vaccine that guides the immune system to create broadly neutralizing antibodies against HIV. For many years, researchers have been trying to develop an HIV vaccine ...

We often hold it to be self-evident that antibodies are key to an effective immune response against a pathogen—the more (or more potent) antibodies your body makes, the better it will fight off an ...

Since it was first identified in 1983, HIV has infected more than 85 million people and caused some 40 million deaths worldwide. While medication known as pre-exposure prophylaxis, or PrEP, can ...

Broadly neutralizing antibodies are already being used to fight viruses. This approach could also help to treat infections with multi-resistant bacteria in the future. Antibiotic-resistant bacteria ...

Discovery brings us one step closer to vaccine and treatment for prevalent virus. Image courtesy of the Centers for Disease Control. Scientists at The University of Texas at Austin, in collaboration ...